Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS · Delayed Price · Currency is USD
31.12
0.00 (0.00%)
Jan 27, 2026, 9:30 AM EST
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$628,950
Profits / Employee
$4,710
Market Cap
53.22B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jushi Holdings | 1,234 |
| MariMed | 832 |
| Glass House Brands | 374 |
| Earth Science Tech | 76 |
| Elite Pharmaceuticals | 68 |
| Radnostix | 42 |
| Healthy Extracts | 2 |
Takeda Pharmaceutical Company News
- 7 days ago - Takeda Announces US Availability Of GAMMAGARD LIQUID ERC For Primary Immunodeficiency Treatment - Nasdaq
- 7 days ago - Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Business Wire
- 8 days ago - Independence Bank of Kentucky Buys 201 Shares of Takeda Pharmaceutical Co Ltd (TAK) - GuruFocus
- 16 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 24 days ago - Takeda Pharmaceutical, Protagonist Therapeutics Announces Submission Of NDA For Rusfertide - Nasdaq
- 24 days ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire
- 6 weeks ago - Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug - Benzinga